Claims for Patent: 8,729,241

Summary for Patent: 8,729,241

Title:	Characterization of O-linked glycans
Abstract:	The present disclosure provides methods for analyzing structure and/or composition of glycoproteins and glycans of glycoproteins. Such methods can include subjecting a glycoprotein preparation to a condition that removes at least one O-linked glycan from the glycoprotein. Such methods can include subjecting a glycoprotein preparation to a condition that releases an N-glycan from the glycoprotein, e.g., prior to subjecting the glycoprotein to a condition that releases an O-glycan from the glycoprotein.
Inventor(s):	Liu; Cuihua (Belmont, MA), Xu; Xiao-Jin (Jamaica Plain, MA), Dong; Shiming (North Reading, MA), Dellorusso; Guy (Milford, MA)
Assignee:	Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	13/140,550
Patent Claims:	1. A method comprising: providing a first glycoprotein preparation of a therapeutic glycoprotein comprising at least one O-linked glycan; subjecting the first glycoprotein preparation to a de-N-glycosylation treatment that removes N-glycans from the glycoprotein preparation; releasing at least one O-linked glycan from a first portion of the treated first glycoprotein preparation by reductive .beta.-elimination, releasing at least one O-linked glycan from a second portion of the treated first glycoprotein preparation by non-reductive .beta.-elimination; and analyzing the released O-linked glycans from the first portion of the treated first glycoprotein preparation and analyzing the released O-linked glycans from the second portion of the treated first glycoprotein preparation. 2. The method of claim 1, wherein released O-glycans from the first or second portions of the treated glycoprotein are labeled. 3. The method of claim 1, further comprising repeating the method with a second glycoprotein preparation of a therapeutic glycoprotein, wherein the second glycoprotein preparation comprises a therapeutic glycoprotein having an amino acid sequence at least 85% identical to an amino acid sequence of the therapeutic glycoprotein in the first glycoprotein preparation. 4. The method of claim 3, further comprising a step of comparing a result of the analysis of the at least one released O-linked glycan obtained from the first glycoprotein preparation with a result of the analysis of the at least one released O-linked glycan obtained from the second glycoprotein preparation. 5. The method of claim 3, wherein the first and second glycoprotein preparations are preparations of the same glycoprotein. 6. The method of claim 3, wherein the first and second glycoprotein preparations are prepared under different conditions. 7. The method of claim 3, wherein the different preparation conditions differ in one or more cell culture parameters selected from the group consisting of continuous feed, batch fee, media, medium, osmolarity, pH, temperature culture time and isolation steps. 8. The method of claim 3, wherein the first and second glycoprotein preparations are preparations from different batches of the glycoprotein prepared by the same method. 9. The method of claim 3, wherein the first and second glycoprotein preparations are preparations from different batches of the glycoprotein prepared by a different method. 10. The method of claim 3, wherein the step of comparing comprises comparing the first results with a historical record of the second results. 11. The method of claim 3 wherein the second glycoprotein preparation comprises a reference glycoprotein. 12. The method of claim 1, wherein the therapeutic glycoprotein is selected from the group consisting of hematologic agents, interferons, colony stimulating factors, antibodies, enzymes and hormones. 13. The method of claim 1, wherein the therapeutic glycoprotein is an antibody. 14. The method of claim 1, wherein the therapeutic glycoprotein is selected from the group consisting of interferon gamma-1b, alteplase; tissue plasminogen activator, Recombinant antihemophilic factor, human albumin, Laronidase, interferon alfa-N3, human leukocyte derived, human antihemophilic factor, virus-filtered human coagulation factor IX, Alefacept; recombinant, dimeric fusion protein LFA3-Ig, Bivalirudin, darbepoetin alfa, Bevacizumab, interferon beta-1a; recombinant, coagulation factor IX, Interferon beta-1b, Tositumomab, antihemophilic factor, human growth hormone, botulinum toxin type A, Alemtuzumab, acritumomab; technetium-99 labeled, alglucerase; modified form of beta-glucocerebrosidase, imiglucerase; recombinant form of beta-glucocerebrosidase, crotalidae polyvalent immune Fab, ovine, digoxin immune Fab, ovine, Rasburicase, Etanercept, epoietin alfa, Cetuximab, algasidase beta, Urofollitropin, follitropin beta, Teriparatide, human somatropin, Glucagon, follitropin alfa, antihemophilic factor, Antihemophilic Factor; Factor XIII, Insulin, antihemophilic factor/von Willebrand factor complex-human, Somatotropin, Adalimumab, human insulin, recombinant human hyaluronidase, interferon alfacon-1, Eptifibatide, alpha-interferon, Palifermin, Anakinra, antihemophilic factor, insulin glargine, granulocyte macrophage colony-stimulating factor, lutropin alfa, for injection, OspA lipoprotein, Ranibizumab, gemtuzumab ozogamicin, Galsulfase, Nesiritide, Pegfilgrastim, Oprelvekin, Filgrastim, Fanolesomab, somatropin [rDNA], insulin; zinc suspension;, insulin; isophane suspension, insulin, regular;, Insulin, coagulation factor VIIa, Somatropin, immunoglobulin intravenous, PEG-L-asparaginase, abatacept, fully human soluable fusion protein, muromomab-CD3, human chorionic gonadotropin, peginterferon alfa-2a, pegylated version of interferon alfa-2b, Abarelix (injectable suspension); gonadotropin-releasing hormone antagonist, epoietin alfa, Aldesleukin, Somatrem, dornase alfa, Efalizumab; selective, reversible T-cell blocker, combination of ribavirin and alpha interferon, Interferon beta 1a, antihemophilic factor, rAHF/ntihemophilic factor, Lepirudin, Infliximab, Abciximab, Reteplase, Rituximab, interferon alfa-2a, Somatropin, synthetic porcine secretin, Basiliximab, Eculizumab, Pegvisomant, Palivizumab; recombinantly produced, humanized mAb, thyrotropin alfa, Tenecteplase, Natalizumab, human immune globulin intravenous 5% and 10% solutions, interferon alfa-n1, lymphoblastoid, drotrecogin alfa, Omalizumab; recombinant DNA-derived humanized monoclonal antibody targeting immunoglobulin-E, Daclizumab, ibritumomab tiuxetan and Somatotropin.

Details for Patent 8,729,241

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2028-12-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2028-12-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2028-12-19
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2028-12-19
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2028-12-19